Value through Innovation27 July 2016

Clinical Study Results

  • BI 2536 - Carcinoma, Small Cell
    Clinical Study Number 1216.11
    Study Indication Carcinoma, Small Cell
    Product BI 2536
    Generic Name BI 2536
    Lab Code
    Clinical Phase II
    Study Title

    An open-label Phase II trial to investigate the efficacy, safety, and pharmacokinetics of a single dose of 200 mg i.v. BI 2536 administered every 21 days in patients with sensitive relapse small cell lung cancer

    Study Document Trial synopsis 1216.11_CO english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.